Background: The follicular variant of papillary thyroid carcinoma (FVPTC) is the second most common subtype of papillary carcinoma after the classical variant. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) has been introduced to standardize the practice of thyroid fine needle aspiration (FNA) reporting. We evaluated the impact of TBSRTC on the FNA interpretation of histologically proven FVPTCs. Method: Cytology reports of 455 histologically proven FVPTCs were reviewed. The rate of each TBSRTC category was compared between pre- and post-TBSRTC eras. Results: The distribution of FNA diagnoses for pre-TBSRTC cases included suspicious for follicular neoplasm (SFN; n = 51, 28.7%), papillary thyroid carcinoma (PTC; n = 47, 26.4%), suspicious for malignancy (SFM; n = 32, 18%), atypia of undetermined significance (AUS; n = 23, 13%), benign (n = 18, 10.1%), and nondiagnostic (ND; n = 7, 4%). Post-TBSRTC diagnoses were: AUS (n = 68, 24.6%), PTC (n = 64, 23.1%), SFM (n = 50, 18%), SFN and benign (n = 42, 15.2%) and ND (n = 11, 4%). SFN rate decreased significantly from 28.7 to 15.2% (p = 0.001) and AUS increased from 12.9 to 24.5% (p = 0.003). Conclusion: Following implementation of TBSRTC, the frequency of AUS diagnoses on FNA prior to surgical resection increased. Given that the rate of FVPTC diagnoses on thyroidectomy increased over the same period, this suggests that the use of AUS has resulted in greater surgical resection of FVPTC.

Renshaw AA, Gould EW: Why there is the tendency to ‘overdiagnose' the follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 2002;117:19-21.
Daniels GH: What if many follicular variant papillary thyroid carcinomas are not malignant? A review of follicular variant papillary thyroid carcinoma and a proposal for a new classification. Endocr Pract 2011;17:768-787.
Goodell WM, Saboorian MH, Ashfaq R: Fine-needle aspiration diagnosis of the follicular variant of papillary carcinoma. Cancer 1998;84:349-354.
Lloyd RV, Erickson LA, Casey MB, et al: Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004;28:1336-1340.
Kurian EM, Dawlett M, Wang J, et al: The triage efficacy of fine needle aspiration biopsy for follicular variant of papillary thyroid carcinoma using the Bethesda reporting guidelines. Diagn Cytopathol 2012;40(suppl 1):E69-E73.
Baloch ZW, Livolsi VA: Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol 2002;117:143-150.
Kesmodel SB, Terhune KP, Canter RJ, et al: The diagnostic dilemma of follicular variant of papillary thyroid carcinoma. Surgery 2003;134:1005-1012; discussion 1012.
Rabaglia JL, Kabbani W, Wallace L, et al: Effect of the Bethesda system for reporting thyroid cytopathology on thyroidectomy rates and malignancy risk in cytologically indeterminate lesions. Surgery 2010;148:1267-1272; discussion 1272-1263.
Sheahan P, Mohamed M, Ryan C, et al: Follicular variant of papillary thyroid carcinoma: differences from conventional disease in cytologic findings and high-risk features. JAMA Otolaryngol Head Neck Surg 2014;140:1117-1123.
Ustun B, Chhieng D, Prasad ML, et al: Follicular variant of papillary thyroid carcinoma: accuracy of FNA diagnosis and implications for patient management. Endocr Pathol 2014;25:257-264.
Lin HS, Komisar A, Opher E, Blaugrund SM: Follicular variant of papillary carcinoma: the diagnostic limitations of preoperative fine-needle aspiration and intraoperative frozen section evaluation. Laryngoscope 2000;110:1431-1436.
Harach HR, Zusman SB: Cytologic findings in the follicular variant of papillary carcinoma of the thyroid. Acta Cytol 1992;36:142-146.
Powari M, Dey P, Saikia UN: Fine needle aspiration cytology of follicular variant of papillary carcinoma of thyroid. Cytopathology 2003;14:212-215.
Caraway NP, Sneige N, Samaan NA: Diagnostic pitfalls in thyroid fine-needle aspiration: a review of 394 cases. Diagn Cytopathol 1993;9:345-350.
Yang J, Schnadig V, Logrono R, Wasserman PG: Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer 2007;111:306-315.
Ali SZ, Cibas ES: The Bethesda System for Reporting Thyroid Cytopathology. Definitions, Criteria and Explanatory Notes. New York, Springer, 2010.
Olson MT, Boonyaarunnate T, Aragon Han P, et al: A tertiary center's experience with second review of 3885 thyroid cytopathology specimens. J Clin Endocrinol Metab 2013;98:1450-1457.
Boonyaarunnate T, Olson MT, Ali SZ: ‘Suspicious for a follicular neoplasm' before and after The Bethesda System for Reporting Thyroid Cytopathology: impact of standardized terminology. Acta Cytol 2013;57:455-463.
Clerici T, Kolb W, Beutner U, et al: Diagnosis and treatment of small follicular thyroid carcinomas. Br J Surg 2010;97:839-844.
Widder S, Guggisberg K, Khalil M, Pasieka JL: A pathologic re-review of follicular thyroid neoplasms: the impact of changing the threshold for the diagnosis of the follicular variant of papillary thyroid carcinoma. Surgery 2008;144:80-85.
Olson MT, Boonyaarunnate T, Altinboga AA, Ali SZ: ‘Suspicious for papillary thyroid carcinoma' before and after The Bethesda System for Reporting Thyroid Cytopathology: impact of standardized terminology. Acta Cytol 2014;58:15-22.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.